

A diverse and broad development pipeline



Late-stage^a

	PHASE 1	PHASE 2	PHASE 3
BRENTUXIMAB VEDOTIN (BV)^b	ECHELON-3: Relapsed/refractory DLBCL (BV + lenalidomide and rituximab vs placebo + lenalidomide and rituximab)		
	CHECKMATE 436 ^c : Relapsed non-Hodgkin lymphoma (BV + nivolumab)		
	CHECKMATE 744: Relapsed/refractory second-line Hodgkin lymphoma in AYA patients (BV + nivolumab)		
	SGN35-015: Frontline Hodgkin lymphoma or PTCL in older patients with significant comorbidities		
	SGN35-027: Frontline early/advanced stage Hodgkin lymphoma (A + AVD with G-CSF primary prophylaxis or AN + AD)		
	SGN35-028: Relapsed/refractory Hodgkin lymphoma or PTCL previously treated with BV-containing regimen		
	SGN35-032: Frontline PTCL with less than 10% CD30 expression (BV + CHP)		
	SGN35-033: Metastatic solid tumors after progression on PD-1 inhibitor treatment (BV + pembrolizumab)		
	SGN35-035: Safety of BV and effect on CD4+ count in HIV		
ENFORTUMAB VEDOTIN (EV)^c	EV-302/KEYNOTE-A39 ^d : Untreated locally advanced or metastatic urothelial cancer (EV + pembrolizumab vs chemotherapy)		
	KEYNOTE-905/EV-303 ^e : MIBC, ineligible for/decline cisplatin (perioperative pembrolizumab ± EV + RC + PLND vs RC + PLND alone)		
	KEYNOTE-B15/EV-304 ^e : Cisplatin-eligible MIBC (perioperative EV + pembrolizumab + RC + PLND vs neoadjuvant chemotherapy + RC + PLND)		
	EV-202: Locally advanced or metastatic malignant solid tumors (EV alone)		
	EV-103/KEYNOTE-869 ^f : Urothelial cancer (EV alone or with other therapies)		
	EV-104: Non-muscle invasive bladder cancer (intravesical EV alone)		
	CompassHER2 RD ^g : High-risk adjuvant HER2+ breast cancer (tucatinib or placebo + T-DM1)		
TUCATINIB	HER2CLIMB-02: HER2+ metastatic breast cancer (tucatinib or placebo + T-DM1)		
	HER2CLIMB-05 ^h : HER2+ metastatic breast cancer maintenance therapy (tucatinib or placebo + trastuzumab + pertuzumab)		
	MOUNTAINEER-03 ^h : HER2+ metastatic colorectal cancer (tucatinib + trastuzumab + mFOLFOX6 vs mFOLFOX6 ± cetuximab or bevacizumab)		
	HER2CLIMB-04: HER2+ metastatic breast cancer (tucatinib + T-DXd)		
	SGNTUC-019: Metastatic solid tumors driven by HER2 alterations (tucatinib + trastuzumab)		
	SGNTUC-024 ⁱ : HER2+ metastatic gastrointestinal cancers (tucatinib + trastuzumab ± pembrolizumab ± FOLFOX or CAPOX)		

^a The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

^b Program being developed in collaboration with Takeda Pharmaceutical Company, Ltd.

^c Program being co-developed with Astellas Pharma Global Development, Inc.

^d Trial being conducted by the Alliance for Clinical Trials in Oncology.

^e Study sponsored by Astellas Pharma Global Development, Inc., in collaboration with Seagen Inc. and Merck Sharp & Dohme LLC

^f Study sponsored by Merck Sharp & Dohme LLC, in collaboration with Seagen Inc. and Astellas Pharma Global Development, Inc.

^h Trial being co-developed with Merck Sharp & Dohme LLC

^j Trial in collaboration with RemeGen Co., Ltd. and Merck Sharp & Dohme LLC

^k Phase 1/2

^l Phase 1b/2

A diverse and broad development pipeline



Late-stage (continued)^a

		PHASE 1	PHASE 2	PHASE 3
TISOTUMAB VEDOTIN (TV) ^e	innovaTV 301: Recurrent or metastatic cervical cancer			
	innovaTV 205 ⁱ : Recurrent or metastatic cervical cancer (monotherapy and in combination with other agents)			
	innovaTV 207: Advanced solid tumors			
LADIRATUZUMAB VEDOTIN (LV) ^j	SGNLVA-005: Locally advanced or metastatic solid tumors			
	SGNLVA-002/KEYNOTE-721 ^k : First-line locally advanced or metastatic triple-negative breast cancer (LV + pembrolizumab)			
	SGNLVA-001: Locally advanced or metastatic breast cancer, including triple-negative breast cancer			
DISITAMAB VEDOTIN (DV)	RC48 G001 ^l : Locally advanced or metastatic urothelial carcinoma with HER2 expression (DV ± pembrolizumab)			

Early-stage^a

SEA-BCMA	SGNBCMA-001: Relapsed/refractory multiple myeloma
SEA-CD40	SGNS40-002: Melanoma and NSCLC (SEA-CD40 ± anti-PD1 ± chemotherapy)
	SGNS40-001: Advanced solid tumors and lymphomas (SEA-CD40 ± anti-PD1 ± chemotherapy)
SEA-CD70	SGNS70-101: Myelodysplastic syndrome and acute myeloid leukemia
SEA-TGT	SGNTGT-001: Advanced solid tumors and lymphomas (SEA-TGT ± sasanlimab)
SGN-ALPV	SGNALPV-001: Advanced solid tumors
SGN-BB228	SGN-BB228-001: Advanced melanoma and solid tumors
SGN-B6A	SGNB6A-001: Advanced solid tumors
SGN-B7H4V	SGNB7H4V-001: Advanced solid tumors
SGN-CD228A	SGN228A-001: Advanced solid tumors
SGN-PDL1V	SGNPDL1V-001: Advanced solid tumors
SGN-STNV	SGNSTNV-001: Advanced solid tumors

^a The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

^e Program being co-developed with Genmab A/S

ⁱ Program being co-developed with Merck Sharp & Dohme LLC

^j Trial in collaboration with RemeGen Co., Ltd. and Merck Sharp & Dohme LLC

^l Phase 1b/2

A + AVD: brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine; AN + AD: brentuximab vedotin, nivolumab, doxorubicin and dacarbazine; AYA: adolescents and young adults; CD: cluster of differentiation; CHP: cyclophosphamide; doxorubicin, and prednisone; DLBCL: diffuse large B-cell lymphoma; G-CSF: granulocyte colony stimulating factors; HER2: human epidermal growth factor receptor 2; HIV: human immunodeficiency virus; MIBC: muscle invasive bladder cancer; NSCLC: non-small cell lung cancer; PD-1: programmed cell death protein 1; PTCL: peripheral T-cell lymphoma; RC + PLND: radical cystectomy plus pelvic lymph node dissection; TDM1: ado-trastuzumab emtansine